Austria - Hong Kong Life Science Exchange

Austrian and Hong Kong Connectors and Innovators Kicked off a Dialogue and Exchange for the Life Science Sector


On Tuesday, 22nd February 2022 ADVANTAGE AUSTRIA Hong Kong together with InvestHK and Life Science Austria held a virtual “Life Science Exchange”. The goal of this virtual meeting between a selected small number of participants was to enable first connections between organisations and companies in this field.The meeting enabled participants to better prepare for personal exchanges when travelling between Europe and Asia will be possible again. As a follow-up, ADVANTAGE AUSTRIA Hong Kong, Life Science Austria and InvestHK will work individually with partcipants to inform and guide them individually towards opportunities. 

During the exchange, Wing-Hin Chung, Head of Investment Promotion and Gregory Rall, Senior Manager Innovation & Technology at InvestHK provided insight into Hong Kong’s Life Science Sector. Wilson Chan, Associate Director at the Hong Kong Science and Technology Parks and Prof Albert Yu from HKBIO gave insight into how to tap into the Hong Kong Market. 

From the Austrian side, Sonja Polan, International Manager, Life Science Austria and Marlis Müllner Director Strategic Investment, ABA - Invest in Austria informed about Austria’s Life Science Sector and opportunities in the Austrian market.  Austria is investing heavily in biotechnology. The combination of global players with research facilities in Austria and young, dynamic  start-ups in close cooperation with excellent  universities creates an ideal environment for  the development, growth and prosperity of the Austrian life science industry. Austria has particular strengths in developing vaccines and drugs for diseases such as cancer and diabetes. New areas of specialism include personalized medicine, wearables, telemedicine and mHealth. The Austrian life science ecosystem includes around 1,000 companies employing over 60,000 people and 55 R&D institutions employing over 24,000 people, see also “Austrian Life Science Directory”.  

Participants also heard introductions of the following Hong Kong and Austrian Life Sciences companies and their experiences, partners wanted: 

Lixin ZHANG-Auberson, MD, PhD, SinoMab:
Biopharmaceutical company for the development of novel drugs 

Dr. Michael Tscheppe, Chief Financial Manager, Blue Sky Immunotherapies:
Next generation immunotherapy against cancer and infectious diseases 

Dr. Christian Harwanegg, CEO, Macro Array Diagnostics:
Multiplex allergy test system with up to 300 allergens

James C.K. Lam, Partnership Manager, Medicus AI:
Helps people to understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.

Click here for Programme
Click here for Presentation- Hong Kong Life Science Sector and Opportunities
Click here for Presentation - Austrian Life Science Sector and Opportunities  
Click here for Video: Austria - Hong Kong Life Science Exchange

The event took place within the framework of the Austrian ReFocus Initiative powered by the Austrian Foreign Ministry and other partners to jump start international business exchanges and opportunities. Austrian Consul General Karl ERNST eelcomed the newly established dialogue which also fits into the ongoing innovation dialogue between Hong Kong SAR and Austria.